Such findings highlighted the possible significance of TUG1 as a predictive marker for exerting CRC response to 5-FU therapy and indicated TUG1 silencing as a novel therapeutic approach to reverse 5-FU resistance [65]. The gene discussed is TUG1; the disease is colorectal carcinoma.